# Weyerhaeuser Co: financial statements, quarterly

WY · NYSE · CIK 106535 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wy.md) · [Financials](/companies/wy/financials.md) · [Filings](/companies/wy/filings.md) · [Insiders](/companies/wy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,022](/filings/0000950170-24-117425.md) | [1,774 d](/filings/0001193125-26-051422.md) | [1,796](/filings/0000950170-25-058770.md) | [1,939](/filings/0000950170-25-098794.md) | [1,681](/filings/0001193125-25-260808.md) | [1,708 d](/filings/0001193125-26-051422.md) | [1,763](/filings/0001193125-26-201473.md) | [1,884](/filings/0001193125-26-328606.md) | [1,717](/filings/0001193125-25-260808.md) | [1,541 d](/filings/0001193125-26-051422.md) | [1,727](/filings/0001193125-26-201473.md) | [1,867](/filings/0001193125-26-328606.md) |
| Cost of revenue | $m | [1,520](/filings/0000950170-24-117425.md) | [1,432 d](/filings/0001193125-26-051422.md) | [1,441](/filings/0000950170-25-058770.md) | [1,535](/filings/0000950170-25-098794.md) | [1,431](/filings/0001193125-25-260808.md) | [1,404 d](/filings/0001193125-26-051422.md) | [1,428](/filings/0001193125-26-201473.md) | [1,559](/filings/0001193125-26-328606.md) | [1,513](/filings/0001193125-25-260808.md) | [1,380 d](/filings/0001193125-26-051422.md) | [1,409](/filings/0001193125-26-201473.md) | [1,556](/filings/0001193125-26-328606.md) |
| Gross profit | $m | [502](/filings/0000950170-24-117425.md) | [342 d](/filings/0001193125-26-051422.md) | [355](/filings/0000950170-25-058770.md) | [404](/filings/0000950170-25-098794.md) | [250](/filings/0001193125-25-260808.md) | [304 d](/filings/0001193125-26-051422.md) | [335](/filings/0001193125-26-201473.md) | [325](/filings/0001193125-26-328606.md) | [204](/filings/0001193125-25-260808.md) | [161 d](/filings/0001193125-26-051422.md) | [318](/filings/0001193125-26-201473.md) | [311](/filings/0001193125-26-328606.md) |
| Research and development | $m | [2.0](/filings/0000950170-24-117425.md) | [2.0 d](/filings/0001193125-26-051422.md) | [1.0](/filings/0000950170-25-058770.md) | [3.0](/filings/0000950170-25-098794.md) | [1.0](/filings/0001193125-25-260808.md) | [2.0 d](/filings/0001193125-26-051422.md) | [1.0](/filings/0001193125-26-201473.md) | [1.0](/filings/0001193125-26-328606.md) | [2.0](/filings/0001193125-25-260808.md) | [1.0 d](/filings/0001193125-26-051422.md) | [1.0](/filings/0001193125-26-201473.md) | [1.0](/filings/0001193125-26-328606.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [353](/filings/0000950170-24-117425.md) | [278 d](/filings/0001193125-26-051422.md) | [196](/filings/0000950170-25-058770.md) | [270](/filings/0000950170-25-098794.md) | [78.0](/filings/0001193125-25-260808.md) | [141 d](/filings/0001193125-26-051422.md) | [179](/filings/0001193125-26-201473.md) | [178](/filings/0001193125-26-328606.md) | [123](/filings/0001193125-25-260808.md) | [251 d](/filings/0001193125-26-051422.md) | [247](/filings/0001193125-26-201473.md) | [223](/filings/0001193125-26-328606.md) |
| Interest expense | $m | [72.0](/filings/0000950170-24-117425.md) | [72.0 d](/filings/0001193125-26-051422.md) | [67.0](/filings/0000950170-25-058770.md) | [67.0](/filings/0000950170-25-098794.md) | [69.0](/filings/0001193125-25-260808.md) | [66.0 d](/filings/0001193125-26-051422.md) | [66.0](/filings/0001193125-26-201473.md) | [66.0](/filings/0001193125-26-328606.md) | [71.0](/filings/0001193125-25-260808.md) | [70.0 d](/filings/0001193125-26-051422.md) | [66.0](/filings/0001193125-26-201473.md) | [66.0](/filings/0001193125-26-328606.md) |
| Income tax | $m | [54.0](/filings/0000950170-24-117425.md) | [(3.0) d](/filings/0001193125-26-051422.md) | [20.0](/filings/0000950170-25-058770.md) | [33.0](/filings/0000950170-25-098794.md) | [(15.0)](/filings/0001193125-25-260808.md) | [(7.0) d](/filings/0001193125-26-051422.md) | [16.0](/filings/0001193125-26-201473.md) | [12.0](/filings/0001193125-26-328606.md) | [(41.0)](/filings/0001193125-25-260808.md) | [(51.0) d](/filings/0001193125-26-051422.md) | [15.0](/filings/0001193125-26-201473.md) | [(15.0)](/filings/0001193125-26-328606.md) |
| Net income | $m | [239](/filings/0000950170-24-117425.md) | [219 d](/filings/0001193125-26-051422.md) | [114](/filings/0000950170-25-058770.md) | [173](/filings/0000950170-25-098794.md) | [28.0](/filings/0001193125-25-260808.md) | [81.0 d](/filings/0001193125-26-051422.md) | [83.0](/filings/0001193125-26-201473.md) | [87.0](/filings/0001193125-26-328606.md) | [80.0](/filings/0001193125-25-260808.md) | [74.0 d](/filings/0001193125-26-051422.md) | [156](/filings/0001193125-26-201473.md) | [162](/filings/0001193125-26-328606.md) |
| Diluted EPS | $ per share | [0.33](/filings/0000950170-24-117425.md) | not reported | [0.16](/filings/0000950170-25-058770.md) | [0.04](/filings/0001193125-25-260808.md) | [0.04](/filings/0001193125-25-260808.md) | not reported | [0.11](/filings/0001193125-26-201473.md) | [0.12](/filings/0001193125-26-328606.md) | [0.11](/filings/0001193125-25-260808.md) | not reported | [0.22](/filings/0001193125-26-201473.md) | [0.23](/filings/0001193125-26-328606.md) |
| Basic EPS | $ per share | [0.33](/filings/0000950170-24-117425.md) | not reported | [0.16](/filings/0000950170-25-058770.md) | [0.04](/filings/0001193125-25-260808.md) | [0.04](/filings/0001193125-25-260808.md) | not reported | [0.11](/filings/0001193125-26-201473.md) | [0.12](/filings/0001193125-26-328606.md) | [0.11](/filings/0001193125-25-260808.md) | not reported | [0.22](/filings/0001193125-26-201473.md) | [0.23](/filings/0001193125-26-328606.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.2](/filings/0000950170-24-117425.md) | [1.2](/filings/0000950170-25-021254.md) | [0.9](/filings/0000950170-25-058770.md) | [1.0](/filings/0000950170-24-086899.md) | [0.9](/filings/0000950170-24-117425.md) | [0.7](/filings/0001193125-26-051422.md) | [0.6](/filings/0000950170-25-058770.md) | [0.6](/filings/0000950170-25-098794.md) | [0.4](/filings/0001193125-25-260808.md) | [0.5](/filings/0001193125-26-328606.md) | [0.3](/filings/0001193125-26-201473.md) | [0.5](/filings/0001193125-26-328606.md) |
| Current assets | $bn | [3.0](/filings/0000950170-23-056022.md) | [2.3](/filings/0000950170-25-021254.md) | [2.1](/filings/0000950170-24-049224.md) | [2.2](/filings/0000950170-24-086899.md) | [2.0](/filings/0000950170-24-117425.md) | [1.7](/filings/0001193125-26-051422.md) | [1.8](/filings/0000950170-25-058770.md) | [1.8](/filings/0000950170-25-098794.md) | [1.6](/filings/0001193125-25-260808.md) | [1.7](/filings/0001193125-26-328606.md) | [1.5](/filings/0001193125-26-201473.md) | [1.6](/filings/0001193125-26-328606.md) |
| Total assets | $bn | [17.6](/filings/0000950170-23-056022.md) | [17.0](/filings/0000950170-25-021254.md) | [16.8](/filings/0000950170-24-049224.md) | [16.8](/filings/0000950170-24-086899.md) | [16.7](/filings/0000950170-24-117425.md) | [16.5](/filings/0001193125-26-051422.md) | [16.5](/filings/0000950170-25-058770.md) | [16.5](/filings/0000950170-25-098794.md) | [16.7](/filings/0001193125-25-260808.md) | [16.6](/filings/0001193125-26-328606.md) | [16.4](/filings/0001193125-26-201473.md) | [16.5](/filings/0001193125-26-328606.md) |
| Current liabilities | $bn | [1.7](/filings/0000950170-23-056022.md) | [0.8](/filings/0000950170-25-021254.md) | [0.9](/filings/0000950170-24-049224.md) | [1.0](/filings/0000950170-24-086899.md) | [1.0](/filings/0000950170-24-117425.md) | [1.0](/filings/0001193125-26-051422.md) | [0.9](/filings/0000950170-25-058770.md) | [1.7](/filings/0000950170-25-098794.md) | [1.3](/filings/0001193125-25-260808.md) | [1.3](/filings/0001193125-26-328606.md) | [1.1](/filings/0001193125-26-201473.md) | [0.9](/filings/0001193125-26-328606.md) |
| Total liabilities | $bn | [7.3](/filings/0000950170-23-056022.md) | [6.7](/filings/0000950170-25-021254.md) | [6.7](/filings/0000950170-24-049224.md) | [6.8](/filings/0000950170-24-086899.md) | [6.7](/filings/0000950170-24-117425.md) | [6.8](/filings/0001193125-26-051422.md) | [6.9](/filings/0000950170-25-058770.md) | [7.0](/filings/0000950170-25-098794.md) | [7.2](/filings/0001193125-25-260808.md) | [7.2](/filings/0001193125-26-328606.md) | [7.0](/filings/0001193125-26-201473.md) | [7.1](/filings/0001193125-26-328606.md) |
| Long-term debt | $bn | [4.8](/filings/0000950170-23-056022.md) | [5.1](/filings/0000950170-25-021254.md) | [4.9](/filings/0000950170-24-049224.md) | [4.9](/filings/0000950170-24-086899.md) | [4.9](/filings/0000950170-24-117425.md) | [4.9](/filings/0001193125-26-051422.md) | [5.0](/filings/0000950170-25-058770.md) | [4.3](/filings/0000950170-25-098794.md) | [4.9](/filings/0001193125-25-260808.md) | [5.1](/filings/0001193125-26-328606.md) | [5.1](/filings/0001193125-26-201473.md) | [5.3](/filings/0001193125-26-328606.md) |
| Current portion of debt | $bn | not reported | [0.0](/filings/0000950170-25-021254.md) | not reported | not reported | not reported | [0.2](/filings/0001193125-26-051422.md) | not reported | not reported | not reported | [0.5](/filings/0001193125-26-051422.md) | not reported | not reported |
| Shareholders' equity | $bn | [10.2](/filings/0000950170-24-117425.md) | [10.2](/filings/0001193125-26-051422.md) | [10.1](/filings/0000950170-25-058770.md) | [10.0](/filings/0000950170-25-098794.md) | [9.9](/filings/0001193125-25-260808.md) | [9.7](/filings/0001193125-26-051422.md) | [9.6](/filings/0001193125-26-201473.md) | [9.5](/filings/0001193125-26-328606.md) | [9.4](/filings/0001193125-25-260808.md) | [9.4](/filings/0001193125-26-328606.md) | [9.4](/filings/0001193125-26-201473.md) | [9.5](/filings/0001193125-26-328606.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [523 d](/filings/0000950170-24-117425.md) | [288 d](/filings/0001193125-26-051422.md) | [124](/filings/0000950170-25-058770.md) | [432 d](/filings/0000950170-25-098794.md) | [234 d](/filings/0001193125-25-260808.md) | [218 d](/filings/0001193125-26-051422.md) | [70.0](/filings/0001193125-26-201473.md) | [396 d](/filings/0001193125-26-328606.md) | [210 d](/filings/0001193125-25-260808.md) | [(114) d](/filings/0001193125-26-051422.md) | [52.0](/filings/0001193125-26-201473.md) | [399 d](/filings/0001193125-26-328606.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [138 d](/filings/0000950170-24-117425.md) | [140 d](/filings/0001193125-26-051422.md) | [248](/filings/0000950170-25-058770.md) | [146 d](/filings/0000950170-25-098794.md) | [145 d](/filings/0001193125-25-260808.md) | [145 d](/filings/0001193125-26-051422.md) | [152](/filings/0001193125-26-201473.md) | [152 d](/filings/0001193125-26-328606.md) | [150 d](/filings/0001193125-25-260808.md) | [152 d](/filings/0001193125-26-051422.md) | [151](/filings/0001193125-26-201473.md) | [152 d](/filings/0001193125-26-328606.md) |
| Share repurchases | $m | [24.0 d](/filings/0000950170-24-117425.md) | [22.0 d](/filings/0001193125-26-051422.md) | [50.0](/filings/0000950170-25-058770.md) | [49.0 d](/filings/0000950170-25-098794.md) | [27.0 d](/filings/0001193125-25-260808.md) | [28.0 d](/filings/0001193125-26-051422.md) | [25.0](/filings/0001193125-26-201473.md) | [100 d](/filings/0001193125-26-328606.md) | [25.0 d](/filings/0001193125-25-260808.md) | [10.0 d](/filings/0001193125-26-051422.md) | [10.0](/filings/0001193125-26-201473.md) | [10.0 d](/filings/0001193125-26-328606.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [741](/filings/0000950170-23-056022.md) | [734](/filings/0000950170-24-049224.md) | [732](/filings/0000950170-24-086899.md) | [732](/filings/0000950170-24-117425.md) | [731](/filings/0000950170-25-058770.md) | [729](/filings/0000950170-25-098794.md) | [728](/filings/0001193125-25-260808.md) | [727](/filings/0001193125-26-201473.md) | [724](/filings/0001193125-26-328606.md) | [722](/filings/0001193125-25-260808.md) | [722](/filings/0001193125-26-201473.md) | [722](/filings/0001193125-26-328606.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 720,736,000 at 2026-07-27, from the cover of the [10-Q filed 2026-07-31](/filings/0001193125-26-328606.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.